Source: UF APK2105 Elite Workbook v2 (Final Edition), Chapters 7 + 8 + 12
Tags: synapse, neurotransmitter, acetylcholine, ACh, nicotinic receptor, neuromuscular junction, NMJ, motor end plate, end-plate potential, EPP, SNARE proteins, synaptic vesicle, calcium, presynaptic terminal, acetylcholinesterase, AChE, GABA, GABA_A receptor, safety factor, ligand-gated channel, exocytosis, UF APK2105
Difficulty: Intermediate | Prerequisites: Neuronal Physiology notes (action potentials, graded potentials, ion channels).
Synaptic transmission is the bridge between one neuron's electrical signal and the next cell's response. At chemical synapses, an action potential triggers neurotransmitter release, which then produces a graded potential on the postsynaptic cell. At the neuromuscular junction (NMJ), this process is highly specialised: a motor neuron releases acetylcholine (ACh) onto a skeletal muscle fibre to initiate contraction. Understanding how presynaptic Ca2+ drives vesicle fusion, how receptors generate postsynaptic potentials, and how the signal is terminated is essential before you can make sense of excitation-contraction coupling or clinical conditions like myasthenia gravis.
An action potential arriving at the presynaptic terminal opens voltage-gated Ca2+ channels, and the resulting calcium influx triggers SNARE-mediated vesicle fusion and neurotransmitter release. At the NMJ, ACh binds nicotinic receptors to produce an end-plate potential that triggers a muscle action potential. Acetylcholinesterase rapidly breaks down ACh to terminate the signal. The NMJ has a built-in "safety factor," meaning it normally releases far more ACh than is needed to reach threshold.
Presynaptic voltage-gated Ca2+ channels
Calcium channels in the axon terminal membrane that open when an action potential arrives. The Ca2+ influx is the direct trigger for synaptic vesicle fusion and neurotransmitter release. Blocking these channels abolishes neurotransmitter release without affecting action potential propagation along the axon.
In simple terms, calcium entering the terminal is the "go" signal for releasing neurotransmitter.
SNARE proteins
A family of proteins (including synaptobrevin, SNAP-25, and syntaxin) that mediate the docking and fusion of synaptic vesicles with the presynaptic membrane. Without functional SNARE proteins, vesicles cannot undergo exocytosis, so no neurotransmitter is released, even though Ca2+ entry is normal.
In simple terms, SNAREs are the molecular machinery that physically merges vesicles with the membrane.
Acetylcholine (ACh)
The neurotransmitter used at the neuromuscular junction and at many synapses in the autonomic and central nervous systems. At the NMJ, it is stored in synaptic vesicles and released by exocytosis.
Nicotinic acetylcholine receptor
A ligand-gated ion channel on the motor end plate that opens when ACh binds to it. It is permeable to both Na+ and K+, but the net effect is Na+ influx, which depolarises the postsynaptic membrane to produce an end-plate potential.
In simple terms, this receptor converts the chemical signal (ACh) back into an electrical signal (depolarization) on the muscle fibre.
End-plate potential (EPP)
The large graded depolarization produced at the motor end plate when ACh binds nicotinic receptors. Under normal conditions, the EPP is always large enough to reach threshold and trigger a muscle action potential.
Acetylcholinesterase (AChE)
An enzyme in the synaptic cleft that rapidly breaks down ACh into acetate and choline, terminating the signal. This is the primary neurotransmitter removal mechanism at the NMJ, more important than diffusion or reuptake at this particular synapse.
Safety factor (of neuromuscular transmission)
The ratio of the actual end-plate potential to the threshold needed for a muscle action potential. Because the NMJ normally releases far more ACh than the minimum required, there is a large safety margin. Reducing receptor density or ACh release shrinks this margin; increasing receptor density or ACh availability enlarges it.
GABA_A receptor
A ligand-gated Cl- channel in the CNS. When GABA binds, the channel opens and Cl- flows into the cell, hyperpolarising it and producing an IPSP. Drugs that enhance GABA_A activity (such as benzodiazepines and barbiturates) increase this inhibitory Cl- influx.
Vesicle docking
The process by which a synaptic vesicle attaches to the presynaptic membrane in preparation for fusion. This step depends on SNARE protein interactions and must occur before Ca2+-triggered exocytosis can happen.
Desensitization (receptor)
When a ligand-gated receptor is continuously exposed to its agonist, it can enter a non-responsive state even while the agonist remains bound. This is clinically relevant when acetylcholinesterase is inhibited: persistent ACh eventually causes nicotinic receptors to desensitise, leading to weakness rather than sustained contraction.
An action potential propagates along the axon and reaches the presynaptic terminal.
The depolarization opens voltage-gated Ca2+ channels, and Ca2+ flows into the terminal down its concentration gradient.
Ca2+ triggers SNARE-mediated fusion of synaptic vesicles with the presynaptic membrane (exocytosis).
Neurotransmitter is released into the synaptic cleft.
Neurotransmitter binds postsynaptic receptors, opening ligand-gated ion channels.
The resulting ion flow produces a postsynaptic potential (EPSP or IPSP depending on the ion and receptor type).
Blocking presynaptic voltage-gated Ca2+ channels produces the greatest decrease in neurotransmitter release while allowing action potentials to propagate normally along the axon (Q3: answer A). This is because Ca2+ channels are only at the terminal, and AP propagation depends on Na+ channels along the axon.
Doubling extracellular Ca2+ around a presynaptic terminal increases neurotransmitter release because more Ca2+ enters during each action potential, driving more vesicle fusion (Q22: answer A).
A toxin blocking presynaptic Ca2+ channels in the CNS leaves action potential propagation along the axon least affected, because AP propagation depends on voltage-gated Na+ channels, not Ca2+ channels (Q43: answer C).
Increasing extracellular Ca2+ at a presynaptic terminal is the intervention that would most increase neurotransmitter release (Q64: answer A).
If SNARE proteins cannot interact with vesicles, vesicle exocytosis fails, neurotransmitter release fails, and no postsynaptic EPSP is generated. However, Ca2+ influx into the axon terminal still occurs normally because it depends on voltage-gated Ca2+ channels, not on SNARE proteins (Q6: answer B).
If a mutation prevents ACh vesicles from docking normally, exocytosis, postsynaptic depolarization, and muscle contraction all fail. Presynaptic depolarization (the action potential arriving at the terminal) still occurs because it does not depend on vesicle machinery (Q29: answer B).
ACh is released from the motor neuron terminal, crosses the synaptic cleft, and binds nicotinic receptors on the motor end plate.
Immediately after ACh binds nicotinic receptors, end-plate depolarization develops (a graded potential, not yet a full action potential) (Q35: answer B).
If the end-plate potential reaches threshold, voltage-gated Na+ channels in the surrounding sarcolemma open, generating a full muscle action potential.
If nicotinic receptors are completely blocked but the muscle fibre is stimulated electrically (bypassing the NMJ), contraction can still occur because the muscle's own excitation-contraction coupling machinery is intact (Q17: answer B).
At the NMJ, the primary mechanism for removing ACh from the synaptic cleft is enzymatic degradation by acetylcholinesterase (Q31: answer C). This is different from many CNS synapses, where reuptake is more important.
Blocking acetylcholinesterase initially strengthens contractions because ACh persists in the cleft and activates more receptors. However, after several minutes, the continuous presence of ACh causes nicotinic receptors to desensitise (become functionally unresponsive), leading to weakness (Q70: answer B).
GABA_A receptors are ligand-gated Cl- channels. When activated, Cl- flows into the cell, producing an IPSP (hyperpolarization).
A drug that enhances GABA_A receptor activity increases Cl- influx, producing greater inhibition (Q32: answer B).
A postsynaptic membrane containing only Cl- channels activated by neurotransmitter binding most likely produces an IPSP (Q28: answer B).
The NMJ normally releases much more ACh than is needed to reach threshold, creating a safety margin.
Increasing nicotinic receptor density on the motor end plate most increases the safety factor, because a given amount of ACh activates more channels and produces a larger EPP (Q42: answer B).
Reducing ACh receptor numbers on the motor end plate most decreases the safety factor, because less current is generated per quantum of ACh released (Q76: answer A).
Normal end-plate potentials but absent muscle action potentials points to defective voltage-gated Na+ channels in the sarcolemma, because the NMJ is working but the signal cannot propagate beyond the end plate (Q47: answer B; Q66: answer A).
Normal muscle contraction with direct electrical stimulation but failure after motor nerve stimulation points to a defect at the neuromuscular junction, because the muscle's own machinery works (Q54: answer A; Q62: answer C).
Bypassing the NMJ by directly depolarising the sarcolemma: a defect in troponin's ability to bind calcium would still completely prevent contraction, because the contractile machinery itself is broken regardless of how the signal arrives (Q78: answer B).
Students often confuse Ca2+ entry at the presynaptic terminal (which triggers neurotransmitter release) with Ca2+ release from the sarcoplasmic reticulum (which triggers muscle contraction). These are two entirely separate calcium events at different locations.
Students sometimes think blocking nicotinic receptors also blocks the muscle's ability to contract. It blocks transmission across the NMJ, but if you electrically stimulate the muscle directly, it still contracts.
Students assume that inhibiting AChE always strengthens the muscle. Initially it does, but sustained ACh exposure desensitises the receptors, eventually causing weakness.
Students mix up the safety factor direction: fewer receptors decreases the safety factor; more receptors increases it.
⚠️ Know the exact sequence: AP arrives at terminal, Ca2+ enters, SNARE-mediated vesicle fusion, ACh release, ACh binds nicotinic receptor, end-plate potential, muscle AP (if threshold reached).
⚠️ Presynaptic Ca2+ questions are common. Ca2+ is specifically for vesicle release, not for AP propagation.
⚠️ AChE inhibition is a two-phase story: initial facilitation, then desensitization-induced weakness. Be prepared for questions that describe both phases.
⚠️ "Normal EPP but no muscle AP" is a classic diagnostic reasoning question pointing to sarcolemma Na+ channels.
⚠️ "Normal contraction with direct stimulation but weakness with nerve stimulation" localises the defect to the NMJ.
True or False: Blocking presynaptic voltage-gated Ca2+ channels prevents action potential propagation along the axon.
Fill in the blank: The primary mechanism for ACh removal at the NMJ is enzymatic degradation by ______.
True or False: SNARE protein dysfunction prevents Ca2+ from entering the presynaptic terminal.
Fill in the blank: GABA_A receptors are ligand-gated ______ channels.
True or False: If nicotinic receptors are blocked, direct electrical stimulation of the muscle fibre cannot produce a contraction.
Answers: 1. False (it prevents neurotransmitter release, not AP propagation). 2. acetylcholinesterase (AChE). 3. False (Ca2+ entry is normal; SNARE dysfunction prevents vesicle fusion). 4. Cl- (chloride). 5. False (the muscle's own excitation-contraction coupling is intact and functions when directly stimulated).
Q: Which intervention produces the greatest decrease in neurotransmitter release while allowing action potentials to propagate normally?
A: Blocking presynaptic voltage-gated Ca2+ channels. This eliminates the calcium signal needed for vesicle fusion without affecting the Na+-dependent action potential propagation along the axon.
Q: A mutation prevents SNARE proteins from interacting with synaptic vesicles. Which event still occurs normally?
A: Calcium influx into the axon terminal. Voltage-gated Ca2+ channels are unaffected by SNARE dysfunction, so Ca2+ still enters when the action potential arrives. What fails is vesicle fusion and everything downstream.
Q: A toxin blocks acetylcholinesterase. Contractions initially strengthen, then muscle weakness develops. What explains the weakness?
A: Nicotinic receptors remain continuously activated by the persistent ACh and become functionally unresponsive (desensitised). The end plate can no longer depolarise effectively despite abundant ACh.
Q: A patient has a normal end-plate potential but no muscle action potentials develop. Where is the defect?
A: The voltage-gated Na+ channels in the sarcolemma. The NMJ is functioning (the end-plate potential is normal), but the graded EPP cannot be converted into a propagating muscle action potential because the Na+ channels needed for that step are defective.
Q: Extracellular Ca2+ concentration around a presynaptic terminal is doubled. What is the most likely response?
A: Increased neurotransmitter release. More Ca2+ enters the terminal with each action potential, triggering fusion of more synaptic vesicles.
Q: Which experimental manipulation would most decrease the safety factor of neuromuscular transmission?
A: Reducing the number of acetylcholine receptors on the motor end plate. This means less depolarization per quantum of ACh released, shrinking the margin between the actual EPP and threshold.
Q: A patient receives a drug that enhances GABA_A receptor activity. What is the immediate effect?
A: Increased Cl- influx into postsynaptic neurons, producing greater inhibition (larger or more prolonged IPSPs) and reducing the likelihood of those neurons firing.
Presynaptic Ca2+ and vesicle release connect back to neuronal physiology (the action potential that opens the Ca2+ channels) and forward to excitation-contraction coupling, where Ca2+ released from the SR triggers crossbridge cycling. The concept of the safety factor is clinically relevant to conditions such as myasthenia gravis (reduced nicotinic receptor density) and Lambert-Eaton syndrome (reduced presynaptic Ca2+ channel function). GABA receptor pharmacology connects to anaesthesiology and anxiolytic drug mechanisms.
synapse, chemical synapse, neurotransmitter release, acetylcholine, ACh, nicotinic receptor, ligand-gated ion channel, motor end plate, end-plate potential, neuromuscular junction, NMJ, SNARE proteins, synaptobrevin, SNAP-25, syntaxin, vesicle exocytosis, presynaptic calcium, voltage-gated calcium channel, acetylcholinesterase, AChE, cholinesterase inhibitor, desensitization, GABA, GABA_A, chloride channel, IPSP, safety factor, myasthenia gravis, Lambert-Eaton, APK2105, UF anatomy and physiology